Rb-82 “ARMI” Trial

Rubidium-82 – An Alternative Radiopharmaceutical for Myocardial Imaging (Rb-ARMI)



Starting in 2014 Canadian Rubidium-82 PET imaging sites will transition from the Rb-ARMI clinical trial to the REST-PET (Rubidium Elution System Testing) device trial. This study will begin with the transition of all the current Rb-ARMI sites in Canada to the REST-PET study to continue development and clinical investigations with the RUBY-FILL® product. This transition is occurring in part, because the RUBY-FILL® generator is approved by Health Canada, but the Elution System is regulated as a medical device, so it must continue to be used under an investigational testing authorization (ITA) until final approval by Health Canada.

Currently, there are five clinical sites in Canada registered under the REST-PET trial: the University of Ottawa Heart Institute (Ottawa, ON) is the study sponsor and coordinating centre / St. Joseph’s Healthcare (Hamilton, ON) / KMH Cardiology (Toronto, ON) / University of Alberta Hospital (Edmonton, AB) and Institut Universitaire de Cardiologie et Pneumologie de Québec (Québec, QC).

For more information on the ARMI Trial, please visit:  www.clinicaltrials.gov/ct2/show/NCT01128023